Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease

Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease

Vo Van Giau,1,* Hyon Lee,2,* Kyu Hwan Shim,1 Eva Bagyinszky,1 Seong Soo A An1 1Department of Bionano Technology, Gachon University, Seongnam, South Korea; 2Department of Neurology, Gachon University Gil Medical Center, Incheon, South Korea *These authors contributed equally to this work Abstract:...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Giau VV, Lee H, Shim KH, Bagyinszky E, An SSA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Alzheimer's disease
CRISPR-Cas9
mutation
Aβ42/40 ratio
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/95bdeabb3b314e69a3cf6babb7dda1da
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:95bdeabb3b314e69a3cf6babb7dda1da
record_format dspace
spelling oai:doaj.org-article:95bdeabb3b314e69a3cf6babb7dda1da2021-12-02T05:19:16ZGenome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease1178-1998https://doaj.org/article/95bdeabb3b314e69a3cf6babb7dda1da2018-02-01T00:00:00Zhttps://www.dovepress.com/genome-editing-applications-of-crispr-cas9-to-promote-in-vitro-studies-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Vo Van Giau,1,* Hyon Lee,2,* Kyu Hwan Shim,1 Eva Bagyinszky,1 Seong Soo A An1 1Department of Bionano Technology, Gachon University, Seongnam, South Korea; 2Department of Neurology, Gachon University Gil Medical Center, Incheon, South Korea *These authors contributed equally to this work Abstract: Genetic variations play an important role in the clinical presentation and progression of Alzheimer’s disease (AD), especially early-onset Alzheimer’s disease. Hundreds of mutations have been reported with the majority resulting from alterations in β-amyloid precursor protein (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) genes. The roles of these mutations in the pathogenesis of AD have been classically confirmed or refuted through functional studies, where the mutations are cloned, inserted into cell lines, and monitored for changes in various properties including cell survival, amyloid production, or Aβ42/40 ratio. However, these verification studies tend to be expensive, time consuming, and inconsistent. Recently, the clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR–Cas9) system was developed, which improves sequence-specific gene editing in cell lines, organs, and animals. CRISPR–Cas9 is a promising tool for the generation of models of human genetic diseases and could facilitate the establishment of new animal AD models and the observation of dynamic bioprocesses in AD. Here, we recapitulated the history of CRISPR technology, recent progress, and, especially, its potential applications in AD-related genetic, animal modeling, and functional studies. Keywords: Alzheimer’s disease, CRISPR–Cas9, mutation, Aβ42/40 ratioGiau VVLee HShim KHBagyinszky EAn SSADove Medical PressarticleAlzheimer's diseaseCRISPR-Cas9mutationAβ42/40 ratioGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 13, Pp 221-233 (2018)
institution DOAJ
collection DOAJ
language EN
topic Alzheimer's disease
CRISPR-Cas9
mutation
Aβ42/40 ratio
Geriatrics
RC952-954.6
spellingShingle Alzheimer's disease
CRISPR-Cas9
mutation
Aβ42/40 ratio
Geriatrics
RC952-954.6
Giau VV
Lee H
Shim KH
Bagyinszky E
An SSA
Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
description Vo Van Giau,1,* Hyon Lee,2,* Kyu Hwan Shim,1 Eva Bagyinszky,1 Seong Soo A An1 1Department of Bionano Technology, Gachon University, Seongnam, South Korea; 2Department of Neurology, Gachon University Gil Medical Center, Incheon, South Korea *These authors contributed equally to this work Abstract: Genetic variations play an important role in the clinical presentation and progression of Alzheimer’s disease (AD), especially early-onset Alzheimer’s disease. Hundreds of mutations have been reported with the majority resulting from alterations in β-amyloid precursor protein (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) genes. The roles of these mutations in the pathogenesis of AD have been classically confirmed or refuted through functional studies, where the mutations are cloned, inserted into cell lines, and monitored for changes in various properties including cell survival, amyloid production, or Aβ42/40 ratio. However, these verification studies tend to be expensive, time consuming, and inconsistent. Recently, the clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR–Cas9) system was developed, which improves sequence-specific gene editing in cell lines, organs, and animals. CRISPR–Cas9 is a promising tool for the generation of models of human genetic diseases and could facilitate the establishment of new animal AD models and the observation of dynamic bioprocesses in AD. Here, we recapitulated the history of CRISPR technology, recent progress, and, especially, its potential applications in AD-related genetic, animal modeling, and functional studies. Keywords: Alzheimer’s disease, CRISPR–Cas9, mutation, Aβ42/40 ratio
format article
author Giau VV
Lee H
Shim KH
Bagyinszky E
An SSA
author_facet Giau VV
Lee H
Shim KH
Bagyinszky E
An SSA
author_sort Giau VV
title Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
title_short Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
title_full Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
title_fullStr Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
title_full_unstemmed Genome-editing applications of CRISPR–Cas9 to promote in vitro studies of Alzheimer’s disease
title_sort genome-editing applications of crispr–cas9 to promote in vitro studies of alzheimer’s disease
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/95bdeabb3b314e69a3cf6babb7dda1da
work_keys_str_mv AT giauvv genomeeditingapplicationsofcrisprndashcas9topromoteinvitrostudiesofalzheimerrsquosdisease
AT leeh genomeeditingapplicationsofcrisprndashcas9topromoteinvitrostudiesofalzheimerrsquosdisease
AT shimkh genomeeditingapplicationsofcrisprndashcas9topromoteinvitrostudiesofalzheimerrsquosdisease
AT bagyinszkye genomeeditingapplicationsofcrisprndashcas9topromoteinvitrostudiesofalzheimerrsquosdisease
AT anssa genomeeditingapplicationsofcrisprndashcas9topromoteinvitrostudiesofalzheimerrsquosdisease
_version_ 1718400484614602752

Ejemplares similares